ISSN: 2148-4902 | E-ISSN: 2536-4553
A single center’s experience of the extrapulmonary neuroendocrine carcinomas [North Clin Istanb]
North Clin Istanb. 2022; 9(1): 35-40 | DOI: 10.14744/nci.2021.47887

A single center’s experience of the extrapulmonary neuroendocrine carcinomas

Emir Celik, Nilay Sengul Samanci, Sumeyra Derin, Sahin Bedir, Ezgi Degerli, Kerem Oruc, Nihan Senturk Oztas, Gulin Alkan, Abdulhalim Senyigit, Hande Turna
Department of Medical Oncology, Istanbul University-Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey

OBJECTIVE: Extrapulmonary neuroendocrine carcinoma (EP-NEC) is a rare tumor type, and a standard therapy for EP-NEC has not yet been established. The purpose of this research was to explore the overall survival (OS) and therapeutic effects of platinum-etoposide combination therapy in EP-NEC.
METHODS: This retrospective study was conducted based on the medical records from January 2010 to March 2020. Eligible patients had been pathologically diagnosed with EP-NEC.
RESULTS: Forty-seven patients were included in the study. About 72.3% (n=34) of the patients were diagnosed with metastatic disease at the first diagnosis. The most common primary tumor site was the stomach. The median progression-free survival (PFS) of the patient group, who received the combination of platinum/etoposide, was 5.83 months (95% CI 4.46–7.20), whereas the median OS of the patients, who were found to have metastatic disease at the first diagnosis, was 13.6 months (95% CI 9.01–18.18). There was no difference in PFS and OS between patients with and without liver metastasis.
CONCLUSION: The outcome of advanced EP-NECs with platinum/etoposide chemotherapy remains poor. Obviously, there is a need for new, more effective treatment options.

Keywords: Extrapulmonary neuroendocrine carcinoma, liver metastasis; platinum and etoposide.

Akciğer dışı nöroendokrin karsinomlar: Tek merkez deneyimi

Emir Celik, Nilay Sengul Samanci, Sumeyra Derin, Sahin Bedir, Ezgi Degerli, Kerem Oruc, Nihan Senturk Oztas, Gulin Alkan, Abdulhalim Senyigit, Hande Turna
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Tıbbi Onkoloji Anabilim Dalı, İstanbul

Giriş: Ekstra-pulmoner nöroendokrin karsinomlar (EP-NEK) nadir görülen tümörlerdir ve standart tedavileri netleşmemiştir. Bu çalışmada amaç platin-etoposid kombinasyonunun sağ kalım ve tedavi etkinliğini araştırmaktır.
Yöntem: Bu retrospektif çalışma, Ocak 2010-Mart 2020 yılları arasındaki tıbbi kayıtlar ile yapıldı. Patolojik olarak EP-NEK tanısı olan hastalar dahil edildi.
Bulgular: Çalışmaya 47 hasta dahil edildi. Hastaların %72.3’ü (n=34) ilk tanıda metastatikti. En sık primer tümör yerleşim yeri mideydi. Platin/etoposid alan hastalarda ortanca progresyonsuz sağ kalım (PSK) 5.83 ay idi (95% CI 4.46-7.20). İlk tanıda metastatik olan hastalarda ortanca genel sağ kalım (GSK) ise 13.6 ay idi (95% CI 9.01-18.18). Karaciğer metastazı olan ve olmayan gruplar arasında PSK ve GSK farkı yoktu.
Sonuç: EP-NEK tanılı hastalarda platin/etoposid tedavi sonuçları yüz güldürücü değildir. Yeni ve daha efektif tedavilere ihtiyaç olduğu aşikardır. (NCI-2020-0334.R1)

Anahtar Kelimeler: Ekstra-pulmoner nöroendokrin karsinom, platin ve etoposid, karaciğer metastazı

Emir Celik, Nilay Sengul Samanci, Sumeyra Derin, Sahin Bedir, Ezgi Degerli, Kerem Oruc, Nihan Senturk Oztas, Gulin Alkan, Abdulhalim Senyigit, Hande Turna. A single center’s experience of the extrapulmonary neuroendocrine carcinomas. North Clin Istanb. 2022; 9(1): 35-40

Corresponding Author: Emir Celik
Manuscript Language: English
LookUs & Online Makale